Q-omics provides the consensus-scored EFCAB14P1 profile across patient tissues and cancer cell-line models. EFCAB14P1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EFCAB14P1 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, EFCAB14P1 RNA expression shows 6,499 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, COAD, and GBM as cancer lineages where EFCAB14P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EFCAB14P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EFCAB14P1 survival associations across molecular data types. EFCAB14P1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EFCAB14P1 RNA expression–survival associations across cancer types. High EFCAB14P1 expression shows unfavorable associations in MESO, DLBC, READ and ESCA, but favorable associations in UCS and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify MESO as the clearest survival context for EFCAB14P1 RNA expression.
This table summarizes EFCAB14P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for EFCAB14P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EFCAB14P1 shows lower tumor expression in THCA and KIRP and higher tumor expression in COAD, LUSC and LIHC. The COAD box plot shows higher EFCAB14P1 RNA expression in tumor versus normal tissue (log2 FC = +0.144, t-test p = .011).
This table shows molecular features associated with EFCAB14P1 in patient tissues and cancer cell lines. In patient samples, EFCAB14P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
